Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Miyoshi, Yasuhide ^a   Noguchi, Kazumi ^a   Yanagisawa, Masahiro ^b   Taguri, Masataka ^b   Morita, Satoshi ^b   Ikeda, Ichiro ^c   Fujinami, Kiyoshi ^a   Miura, Takeshi ^d   Kobayashi, Kazuki ^e   Uemura, Hiroji ^b  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c Yokohama Minami Kyosai Hospital   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e YOKOSUKA KYOSAI HOSPITAL   (Japan)

Author keywords

Bone metastasis; Nomogram; Prognostic tool; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER STAGING; CAUSE OF DEATH; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OVERALL SURVIVAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; VALIDATION STUDY; BLOOD; BONE TUMOR; CANCER GRADING; DISEASE FREE SURVIVAL; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NOMOGRAMS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84928784979     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1330-x     Document Type: Article

References (25)

1. Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer Incidence and Incidence Rates in Japan in 2008: A Study of 25 Population-based Cancer Registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol. 2013;44(4):388-96.
2. Huggins C, Hodges CV. Studies on prostatic cancer I: the effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-7.
3. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol. 1997;15(1):382-8.
4. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol. 1998;160(4):1220-9.
5. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339(15):1036-42.
6. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355(9214):1491-8.
7. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-20.
8. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-54.
9. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22.
10. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
11. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375(9724):1437-46.
12. Miyoshi Y, Uemura H, Nakamura M, Hasumi H, Sugiura S, Makiyama K, et al. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients. Int J Clin Oncol. 2005;10(3):182-6.
13. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol. 2009;27(26):4306-13.
14. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61(1):195-202.
15. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364-70.
16. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007;13(21):6396-403.
17. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2010;16(1):203-11.
18. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20(19):3972-82.
19. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21(7):1232-7.
20. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol. 2009;27(17):2766-71.
21. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27(32):5431-8.
22. Dellis A, Papatsoris AG. The economics of abiraterone acetate for castration-resistant prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2014;14(2):175-9.
23. Tewari A, Raman JD, Chang P, Rao S, Divine G, Menon M. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy). Urology. 2006;68(6):1268-74.
24. Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int. 2010;106(4):462-9.
25. Mikkola A, Aro J, Rannikko S, Ruutu M, Finnprostate G. Prognostic grouping of metastatic prostate cancer using conventional pretreatment prognostic factors. Scand J Urol Nephrol. 2009;43(4):265-70.